UCB (STU:UNC) Inventories, Raw Materials & Components: €229 Mil (As of Dec. 2025)


STU:UNC UCB SA STU:UNC
90 GF Score
Price €257.70
GF Value €210.81
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is UCB Inventories, Raw Materials & Components?

UCB STU:UNC -1.68% 90 Inventories, Raw Materials & Components is €229 Mil as of Dec. 2025. GuruFocus rates STU:UNC with a GF Score™ of 90/100 and a GF Value™ of €210.81 (Modestly Overvalued). The stock has 2 warning signs investors should review.

UCB's inventories, raw materials & components for the quarter that ended in Dec. 2025 was €229 Mil.

UCB's quarterly raw materials declined from Dec. 2024 (€167 Mil) to Jun. 2025 (€0 Mil) but then increased from Jun. 2025 (€0 Mil) to Dec. 2025 (€229 Mil).

UCB's annual raw materials increased from Dec. 2023 (€161 Mil) to Dec. 2024 (€167 Mil) and increased from Dec. 2024 (€167 Mil) to Dec. 2025 (€229 Mil).

UCB Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for UCB's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UCB Inventories, Raw Materials & Components Chart

UCB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 100.00 121.00 161.00 167.00 229.00

UCB Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 161.00 0.00 167.00 0.00 229.00
STU:UNC
90GF Score
UCB SA STU:UNC
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UCB Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of €229 Mil mean?
UCB (STU:UNC) has a Inventories, Raw Materials & Components of €229 Mil as of Dec. 2025. Raw materials are the components a company uses for its main products. View historical data on UCB and its competitors.
Is UCB's Inventories, Raw Materials & Components too high?
UCB's current Inventories, Raw Materials & Components is €229 Mil. Overall, UCB has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UCB's Inventories, Raw Materials & Components compare to VRTX and REGN?
UCB's Inventories, Raw Materials & Components of €229 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on UCB and its competitors. UCB's current Inventories, Raw Materials & Components is €229 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
Based on GuruFocus' analysis, UCB (STU:UNC) is currently considered Modestly Overvalued. The stock's GF Value™ is €210.81, compared to a current price of €257.70 — trading 22.2% above its estimated fair value. The current Inventories, Raw Materials & Components is €229 Mil. UCB's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For UCB (STU:UNC), the current Inventories, Raw Materials & Components is €229 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UCB (STU:UNC) Overvalued in 2026?

Based on GuruFocus' analysis, UCB stock appears to be overvalued. The current stock price of €257.70 is trading 22.2% above its estimated GF Value™ of €210.81. GuruFocus considers UCB to be Modestly Overvalued.

Key valuation signals for STU:UNC:

  • Inventories, Raw Materials & Components: €229 Mil
  • GF Value™: €210.81 vs. price of €257.70 (22.2% above fair value)
  • GF Score™: 90/100 with 2 warning signs

No single metric tells the full story. See the STU:UNC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UCB Business Description

Address Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
90GF Score

Get the complete analysis for STU:UNC

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€257.70
Price
€210.81
GF Value